Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
Public ClinicalTrials.gov record NCT05928390. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind Randomized Placebo-controlled Dose-finding Phase II Study to Assess the Efficacy and Safety of Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The Total duration of trial participation for each participant with post-bariatric hypoglycemia will be a maximum of 59 weeks, with the following duration of trial periods * 19 weeks for the Core Phase. It is composed of: * a Screening period: a maximum of 3 weeks * a Run-in period (no treatment): 4 weeks * a Blinded Treatment Phase: 12 weeks * 36 weeks Extension Phase = an open-label Treatment period * 4 weeks for the safety follow-up period (without any treatment).
Study identification
- NCT ID
- NCT05928390
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 93 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 4, 2024 (Actual)
- Primary completion
- Oct 29, 2026 (Estimated)
- Completion
- Oct 29, 2026 (Estimated)
- Last update posted
- Sep 17, 2026
2024 – 2026
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University School of Medicine, Endocrinology, 800 Welch Road, | Palo Alto | California | 94305 | — |
| Northwestern University - Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois | 60628 | — |
| NOLA Care | Metairie | Louisiana | 70006 | — |
| Velocity Clinical Research - Annapolis | Annapolis | Maryland | 21401 | — |
| Joslin Diabetes CenterJoslin Diabetes Center, One Joslin Place | Boston | Massachusetts | 02215 | — |
| Mayo Clinic - Rochester, 200 First Street, SW, 55905 | Rochester | Minnesota | 55905 | — |
| Montefiore Medical Center, 111 E 210th Street, | The Bronx | New York | 10467 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37204 | — |
| University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, | San Antonio | Texas | 78229 | — |
| University of Wisconsin Health W. E. Clinic END, 451 Junction Rd, | Madison | Wisconsin | 53717 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05928390, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 17, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05928390 live on ClinicalTrials.gov.